G

GoodRx

Prescription price comparison and coupons

GTM Manager - Media Strategy & Execution

Full-Time
$102k - $216k
Senior
Bachelor's
Remote in USA
Remote
Growth & MarketingProduct Marketing

About the job

Requirements
  • A bachelor's degree is required.
  • 5–8 years of experience in go-to-market, product marketing, sales enablement, commercialization, media strategy, integrated marketing, or a related field.
  • Experience in pharmaceutical or healthcare media, life sciences marketing, digital health, healthcare advertising, or an adjacent environment is strongly preferred.
  • Demonstrated experience supporting product or feature launches and coordinating cross-functional go-to-market execution.
  • Experience developing positioning, sales collateral, value propositions, launch materials, training, or other commercial enablement programs.
  • Strong understanding of digital media and omnichannel marketing concepts, including healthcare professional and/or direct-to-consumer activation, audience strategy, measurement, and agency buying dynamics.
  • Comfort working with packaging, rate cards, and commercial frameworks, with the ability to translate strategic direction into clear field guidance.
  • Strong project management, prioritization, and stakeholder-coordination skills, with the ability to drive work from strategy through launch and iteration without direct authority.
Responsibilities
  • Translate healthcare professional and direct-to-consumer media strategy into quarterly and in-market activation plans, workplans, deliverables, owners, and timelines.
  • Drive launch and rollout plans for new capabilities, sponsorships, and packages by identifying dependencies, risks, and decision points early.
  • Coordinate cross-functional launch readiness across Sales, Product, Analytics, Marketing, Legal, Client Success, and Revenue Operations.
  • Support high-priority pitches, requests for proposals, agency conversations, and strategic client opportunities with tailored narratives, solution recommendations, and commercial materials.
  • Partner with Product, Analytics, and Insights teams to turn capabilities and performance evidence into differentiated value propositions and commercially relevant proof points.
  • Monitor competitor activity, pharmaceutical industry trends, agency behavior, and market feedback to inform messaging and near-term go-to-market tactics.
  • Own and maintain core sales enablement materials, including one-pagers, solution narratives, FAQs, talk tracks, and the sales enablement collateral process.
  • Translate complex sponsorship capabilities, product updates, measurement approaches, and strategic positioning into clear, compelling stories for pharmaceutical brands and agencies.
  • Coordinate internal training sessions, launch briefings, and written follow-ups to build seller fluency and reinforce consistent positioning.
  • Partner with Sales and Client Success to identify recurring questions, objections, and enablement gaps, then prioritize updates to tools and training.
  • Maintain a reliable source of truth for approved commercial materials and communicate meaningful updates to the field.
  • Establish structured feedback loops with Sales and cross-functional partners to understand which messages, tools, use cases, and solutions are resonating.
  • Capture post-launch, win/loss, customer, and field learnings and translate them into recommendations for positioning, enablement, execution, and future go-to-market strategy.
  • Create repeatable launch, enablement, request-for-proposal, and commercialization frameworks that improve speed, consistency, and scalability.
Desired Qualifications
  • Business, marketing, media, healthcare, or a related field is preferred.
  • Experience in pharmaceutical or healthcare media, life sciences marketing, digital health, healthcare advertising, or an adjacent environment is strongly preferred.

About the company

G

GoodRx

View
cbWebsite

GoodRx provides price comparisons, coupons, and discounts for prescription medications through its website and mobile app. It partners with pharmacies to offer savings at the point of sale, earning referral fees. It also offers GoodRx Gold subscription with deeper discounts and earns revenue from ads and partnerships. The goal is to save people money on prescriptions and improve access to affordable medicines.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Santa Monica, California

Founded

2005

Get referred to GoodRx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 subscription revenue rose 39% to $28.5 million, expanding recurring income.
  • Pharma Direct revenue jumped 76% in Q2 2026, driven by GLP-1 access programs.
  • Employer Direct launches in 2027 can subsidize Companion and lower consumer acquisition costs.

What critics are saying

  • Q2 2026 revenue fell 1%; coupon pricing remains commoditized against SingleCare and Amazon Pharmacy.
  • FTC's 2023 privacy order still shadows GoodRx and blocks trust-driven ad monetization.
  • If pharmacy partners tighten spreads or CVS access weakens, referral revenue erodes quickly.

What makes GoodRx unique

  • GoodRx launched Companion Family Plan on September 3, 2026, covering households and pets.
  • GoodRx combines pharmacy discounts, $19 telehealth, dental, vision, lab, and imaging savings.
  • GoodRx has access across nearly every U.S. pharmacy and 250 free generics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical, dental, and vision insurance
  • 401(k) with a company match
  • ESPP
  • Unlimited vacation
  • "Take care of yourself" days
  • 11 paid holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Subscription Insider
Sep 9th, 2026
GoodRx expands Companion membership to families and pets.

GoodRx expands Companion membership to families and pets. GoodRx is expanding Companion, the paid membership it is making central to its subscription strategy, from an individual product to a family plan that can also include pets. Companion is a prescription and healthcare discount membership. It is not health insurance. GoodRx launched the Companion Family Plan on September 3 for $24.99 per month, or $16.99 per month when paid annually. A primary member can add up to four dependents, including children, adult family members and pets. There are no age restrictions for human dependents. The individual Companion membership, introduced in May, costs $14.99 per month or the equivalent of $9.99 per month when paid annually. For monthly subscribers, moving to the Family Plan costs another $10 and can extend access to four additional family members or pets. For annual subscribers, the difference is $7 per month on an equivalent monthly basis. GoodRx said at launch that Companion Family provides access to more than 250 eligible generic medications at no additional cost, with hundreds of additional medications available for less than $10. The company also offers discounts on services including dental, vision, lab and imaging. The benefits aren't identical for everyone on the plan. Under GoodRx's terms, add-on family members don't receive discounted telehealth services. Pets can receive prescription savings but don't receive telehealth or discounts for healthcare services such as dental and vision. Some benefits, including discounted online care, remain with the primary member. Availability can also vary by location. Companion is not currently available in Washington state, and some healthcare benefits vary by state. GoodRx plans to offer Companion through its Employer Direct business beginning in 2027. Employers will be able to subsidize some or all of the membership cost, opening another path for GoodRx to reach members beyond direct consumer acquisition. The Family Plan arrives as subscriptions take a larger role in GoodRx's business. Subscription revenue increased 39% to $28.5 million in the second quarter, and GoodRx ended June with 764,000 subscription plans, up from 668,000 a year earlier. Subscription Insider reported in August that GoodRx was shifting more product and marketing investment toward subscriptions and making Companion its primary subscription offering. Family memberships themselves aren't new to GoodRx. GoodRx Gold and RxSmartSaver+ already allow multiple members on some plans. What's new is the expansion of Companion, the product GoodRx is now putting at the center of its subscription strategy. Insider take. GoodRx gives subscription operators a useful example of what changes when one paying customer can extend a membership to more of the family. The customer math is easy to see. Pay more each month and several people or pets can find value in the same membership. The operator math is harder. More covered members could make Companion harder to cancel because its value is spread across the family. But those additional members can also use more benefits, which may make the plan more expensive to serve. GoodRx has made choices about that tradeoff. Some benefits can be shared. Others stay with the primary member, and pets receive a narrower set of benefits. That's the part operators should watch. Expanding a membership isn't only about how many people can join. It's also about deciding which benefits can travel with them and which should remain limited. Subscription Insider won't know yet whether GoodRx got that balance right. The useful numbers will come later: how many individual members move to Family, how much the added benefits get used and whether those families stay longer. The test is whether broader access makes the membership more valuable to keep without making it too expensive to serve. Related Member Resource If you're considering adding or expanding a paid membership inside a larger business, this resource helps you work through what changes across customer value, revenue, renewal, and the economics of the broader business. It includes a transition scorecard to help you assess the shift.

Chain Drug Review
Sep 3rd, 2026
GoodRx expands subscription strategy with Companion Family Plan.

GoodRx expands subscription strategy with Companion Family Plan. New $24.99 monthly plan includes a primary member and up to four dependents, including children, adults, and pets, with more than 250 generic medications available for free and savings on dental, vision, lab and imaging services. September 3, 2026. 9:17 AM SANTA MONICA, Calif. - GoodRx today launched the Companion Family Plan, expanding its everyday healthcare subscription to entire households, including children, adult family members, and pets. As widening coverage gaps and rising out-of-pocket costs leave households paying more for care, the new plan brings Companion's free and low-cost prescriptions and savings on common healthcare services together in one affordable, predictably priced membership. "Families don't experience healthcare costs one person at a time. They're simultaneously managing prescriptions and care for kids, parents, partners, and even pets," said Wendy Barnes, President and CEO of GoodRx. "Expanding Companion across the entire household allows us to support consumers in a way that reflects this reality. It also advances our strategy to make GoodRx a more central part of how consumers navigate and pay for healthcare." One Plan. More Ways for Families to Save. The Companion Family Plan, which costs $24.99 per month or $16.99 per month when paying annually, extends Companion benefits to a primary member and up to four dependents, which may include children, adult family members, and pets. Members can access more than 250 eligible generic medications for free and hundreds more for under $10 at nearly every pharmacy nationwide, plus savings on dental, vision, lab and imaging services. The primary member also receives access to $19 online care visits. Together, these features give families an affordable and predictable way to save across prescriptions and common healthcare needs. Building a Broader Subscription Offering The Companion Family Plan expands the reach and value of GoodRx's subscription offering, creating a more continuous way to support consumers beyond individual prescription transactions. Building on more than a decade of medication pricing expertise, extensive relationships with retail pharmacies, and a trusted consumer brand, GoodRx is uniquely positioned to scale this model. Companion complements the company's condition-focused offerings for weight loss, erectile dysfunction, and hair loss. Supporting Growth and Retention for Retail Pharmacy Partners Companion gives members access to meaningfully lower prices than they would receive through a traditional prescription discount, while allowing them to continue filling at the pharmacies they already know and trust. This helps retail pharmacy partners strengthen patient relationships, support prescription volume, and deliver a more compelling consumer experience, with no additional cost to participate. The Companion Family Plan broadens those benefits while preserving favorable pharmacy economics and reinforcing the value of GoodRx's retail pharmacy network. Making Companion an Employee Benefit GoodRx plans to offer Companion through Employer Direct, giving employers a flexible, predictable way to subsidize memberships and help lower employees' out-of-pocket healthcare costs. Companion can complement existing health benefits by addressing prescription costs and other coverage gaps, or extend healthcare savings to workers who are not eligible for traditional benefits. The expansion creates a new channel for Companion while giving employers another way to support healthcare affordability for their workforce. Get the latest Chain Drug Review news delivered straight to your inbox. Have news to share? Send Chain Drug Review your press releases and announcements.

MarketBeat
Aug 26th, 2026
GoodRx (NASDAQ:GDRX) major shareholder sells $437,819.12 in stock.

GoodRx (NASDAQ:GDRX) major shareholder sells $437,819.12 in stock. August 26, 2026 Key points. * Francisco Partners IV sold 127,273 GoodRx shares for $437,819 at an average price of $3.44, reducing its ownership by 16.51% to 643,466 shares. The shareholder also sold more than 2.6 million additional shares in transactions from August 19-26. * GoodRx shares rose 5.2% to $3.65, giving the company a market capitalization of approximately $1.25 billion. Its latest quarterly results matched earnings expectations at $0.08 per share and exceeded revenue estimates, although revenue declined 1.3% year over year. * Analyst sentiment remains mixed, with four Buy, six Hold and three Sell ratings and a consensus price target of $4.23. Recent target changes included UBS raising its target to $3.75 and Citigroup increasing its target to $5.00. * Interested in GoodRx? Here are five stocks we like better. GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $3.44, for a total value of $437,819.12. Following the completion of the transaction, the insider directly owned 643,466 shares of the company's stock, valued at approximately $2,213,523.04. This trade represents a 16.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC. Francisco Partners Iv, L.P. also recently made the following trade(s): * On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. * On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The shares were sold at an average price of $3.46, for a total value of $496,835.24. * On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50. * On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68. * On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total transaction of $1,666,071.75. GoodRx stock up 5.2%. NASDAQ:GDRX traded up $0.18 during trading hours on Wednesday, reaching $3.65. The company had a trading volume of 3,534,816 shares, compared to its average volume of 1,909,305. GoodRx Holdings, Inc. has a twelve month low of $1.77 and a twelve month high of $5.81. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of 91.27, a P/E/G ratio of 1.73 and a beta of 1.60. The business's 50-day simple moving average is $3.18 and its two-hundred day simple moving average is $2.66. Discover more Integrated Circuits Stock Screener Tool Financial Markets News GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The firm had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business's quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.09 earnings per share. On average, equities analysts expect that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current year. Analyst ratings changes. A number of research firms recently weighed in on GDRX. Weiss Ratings raised GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, August 7th. UBS Group upped their target price on GoodRx from $2.50 to $3.75 and gave the stock a "neutral" rating in a research report on Thursday, August 13th. Wall Street Zen upgraded GoodRx from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Citigroup lifted their price target on shares of GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Finally, Leerink Partners set a $5.00 price target on shares of GoodRx in a research note on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, GoodRx has an average rating of "Hold" and a consensus target price of $4.23. Institutional inflows and outflows. A number of large investors have recently modified their holdings of the stock. Lazard Asset Management LLC grew its holdings in GoodRx by 43.6% during the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock worth $85,000 after buying an additional 5,201 shares in the last quarter. Brevan Howard Capital Management LP lifted its stake in GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company's stock valued at $404,000 after acquiring an additional 6,842 shares in the last quarter. Hirtle Callaghan & Co LLC lifted its stake in GoodRx by 60.3% during the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company's stock valued at $49,000 after acquiring an additional 6,869 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in GoodRx by 202.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock valued at $56,000 after acquiring an additional 7,580 shares in the last quarter. Finally, Quarry LP purchased a new position in GoodRx during the 3rd quarter worth $33,000. Institutional investors own 63.77% of the company's stock. About GoodRx. GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications. In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider GoodRx, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list. While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Yahoo Finance
Aug 14th, 2026
GoodRx reports Q2 revenues of $200M, delivers slowest growth among healthcare tech peers

GoodRx reported second-quarter revenues of $200.4 million, down 1.3% year-on-year but exceeding analyst expectations by 3.5%. The prescription drug price comparison platform delivered the slowest revenue growth among seven healthcare technology stocks tracked in the analysis. Despite the modest performance, GoodRx provided strong forward guidance. Its full-year revenue and EBITDA forecasts both topped analyst expectations. The stock has responded positively, rising 14.1% since the earnings announcement and currently trading at $3.73. The company, founded in 2011, helps consumers find lower prescription medication prices through comparison tools and discount codes. The healthcare technology sector as a group reported strong results, with revenues beating consensus estimates by 3.7% and next quarter guidance exceeding expectations by 2.8%. Share prices across the sector have risen 6.8% on average following the latest earnings.

MarketBeat
Aug 11th, 2026
GoodRx (NASDAQ:GDRX) stock price expected to rise, Citigroup Analyst says.

GoodRx (NASDAQ:GDRX) stock price expected to rise, Citigroup Analyst says. August 11, 2026 Key points. * Citigroup raised GoodRx's price target from $4.00 to $5.00 and maintained a "buy" rating, implying 31.41% upside from the previous close. * Analyst sentiment remains mixed: GoodRx has an average "Hold" rating and a consensus price target of $4.16, while Wells Fargo and TD Cowen also raised their targets to $5.00. * GoodRx reported quarterly EPS of $0.08, in line with estimates, and revenue of $200.41 million, above expectations but down 1.3% year over year. The stock recently traded at $3.81, while institutional investors own 63.77% of shares. * MarketBeat previews the top five stocks to own by September 1st. GoodRx (NASDAQ:GDRX - Get Free Report) had its price target increased by analysts at Citigroup from $4.00 to $5.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Citigroup's price objective indicates a potential upside of 31.41% from the company's previous close. A number of other analysts also recently weighed in on the company. The Goldman Sachs Group reiterated a "neutral" rating and set a $4.00 price target on shares of GoodRx in a report on Friday. Wells Fargo & Company upped their target price on GoodRx from $3.50 to $5.00 and gave the company an "overweight" rating in a research report on Friday. TD Cowen lifted their target price on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Tuesday. Leerink Partners set a $5.00 price target on GoodRx in a report on Thursday. Finally, Weiss Ratings upgraded shares of GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, GoodRx currently has an average rating of "Hold" and an average price target of $4.16. GoodRx price performance. GDRX stock traded up $0.14 during midday trading on Tuesday, reaching $3.81. 1,750,660 shares of the stock were exchanged, compared to its average volume of 2,112,026. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81. The company has a fifty day moving average price of $2.96 and a 200 day moving average price of $2.55. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a market capitalization of $1.30 billion, a PE ratio of 95.15, a P/E/G ratio of 1.70 and a beta of 1.60. GoodRx (NASDAQ:GDRX - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, meeting the consensus estimate of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. During the same period last year, the company earned $0.09 earnings per share. The business's quarterly revenue was down 1.3% on a year-over-year basis. As a group, analysts expect that GoodRx will post 0.17 EPS for the current fiscal year. Institutional inflows and outflows. A number of large investors have recently made changes to their positions in the business. Prescott Group Capital Management L.L.C. bought a new stake in shares of GoodRx during the fourth quarter worth about $4,812,000. Technology Crossover Management X Ltd. acquired a new position in GoodRx during the 2nd quarter valued at about $4,762,000. Northwestern Mutual Wealth Management Co. boosted its stake in GoodRx by 10,242.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company's stock valued at $4,072,000 after purchasing an additional 1,488,137 shares during the last quarter. AQR Capital Management LLC increased its holdings in GoodRx by 188.0% during the 4th quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company's stock worth $3,140,000 after purchasing an additional 756,209 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in GoodRx by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company's stock worth $38,947,000 after purchasing an additional 624,182 shares in the last quarter. 63.77% of the stock is owned by institutional investors. GoodRx company profile. GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications. In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider GoodRx, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list. While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.